Trials / Completed
CompletedNCT01578057
Evaluation of the Pharmacodynamic and Pharmacokinetic Interactions of Tasimelteon and Ethanol
A Randomized, Double-mask, Four-period Crossover Study in Healthy Subjects to Evaluate the Pharmacodynamic and Pharmacokinetic Interactions of Tasimelteon and Ethanol
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Vanda Pharmaceuticals · Industry
- Sex
- Female
- Age
- 19 Years – 79 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this research study is to understand if there is any difference in the effects of tasimelteon when it is taken alone or in combination with alcohol. This research study is also being done to understand if there is any difference in the amount of tasimelteon (and its breakdown products) or alcohol in the blood when taken alone or together. Finally, the study will also look at the safety and tolerability (how acceptable it is) of tasimelteon.
Detailed description
Alcohol is a drug that gets absorbed into the bloodstream quickly. The blood carries the alcohol to the brain where it slows down the messages in the brain (alcohol is a depressant). Alcohol affects a person's memory, behaviour, concentration, alertness (your thought process is slower), and coordination (your movements become clumsy). The intended effect of tasimelteon is to cause sleepiness. Sleepiness may result in similar effects on memory, concentration, alertness, and coordination as alcohol. There is the possibility taking tasimelteon and alcohol together can make these effects stronger or worse.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tasimelteon | 20mg, once |
| DRUG | Ethanol | 0.6 g/kg ethanol (women) or 0.7 g/kg ethanol (men) in a total volume of 300 mL as a light cranberry juice cocktail, (consumed within 15 minutes). |
| OTHER | Placebo tasimelteon | once |
| DRUG | Placebo ethanol | A total volume of 300 mL as a light cranberry cocktail (consumed within 15 minutes) with about 1 mL of supernatant of ethanol in the top |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2012-06-01
- Completion
- 2012-06-01
- First posted
- 2012-04-16
- Last updated
- 2014-02-17
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01578057. Inclusion in this directory is not an endorsement.